Summary

Asia-Pacific Vaccines Market
The Asia-Pacific vaccines market was valued at $9.8 billion in 2023 and is projected to reach $19.9 billion by 2033, growing at a CAGR of 7.3% from 2024 to 2033.
A vaccine is a biological preparation designed to protect against infectious diseases. It contains whole or specific components of pathogens (viruses, bacteria, or toxins) that stimulate the immune system to initiate a defense without causing illness. Key components of a vaccine include antigens, adjuvants, stabilizers, and preservatives. The different types of vaccines include inactivated, subunit, live attenuated, toxoid, and DNA or mRNA vaccines, each consisting of distinct mechanisms to activate the immune response.

Increase in the incidence and re-emergence of infectious diseases in the region is a key driver of the Asia-Pacific vaccines market. In addition, as the governments of different nations are strengthening their policies of offering certain vaccines free of cost, such as the Universal Immunization Program in India and the Expanded Program on Immunization in China, the Asia-Pacific vaccines market is witnessing significant development. Currently, vaccine manufacturers in Asia-Pacific are focusing on the adoption of AI to accelerate the development timelines and reduce manufacturing costs. The synergy of AI with computational immunology is trending due to the capabilities of ML algorithms to accelerate vaccine discovery through extensive dataset examination and predict immune responses with precision.

However, disruptions in the supply chain of vaccines in remote and underserved areas due to lack of efficient cold chain infrastructure hampers the development of the Asia-Pacific vaccines market. Moreover, rise in the prevalence of disease variants due to frequent mutations in microorganisms is resulting in vaccine ineffectiveness, which is restraining the market growth significantly. On the contrary, as the industry players are shifting their focus toward the development of therapeutic vaccines, the Asia-Pacific vaccines market is poised to witness several remunerative opportunities in the coming years. According to an article published in the Asia Edition of BioSpectrum—an Indian biotech magazine—Asia-Pacific conducted around 46% of global prophylactic vaccine trials and 31% of therapeutic vaccine trials in 2024, emerging as a powerhouse in vaccine development. The robust clinical trial infrastructure of the region highlights the crucial role of the Asia-Pacific vaccines market in shaping the future of global vaccine innovation.

Segment Review
The Asia-Pacific vaccines market is segmented into technology type, indication, end user, and region. On the basis of technology type, the market is divided into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. As per indication, it is categorized into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, & rubella, diphtheria, pertussis, & tetanus (DTP); polio; hepatitis; and other indications. By end user, it is classified into pediatric, adults, and travelers. Country wise, it is analyzed across Japan, China, India, Australia, South Korea, and rest of Asia-Pacific.

Key Findings
On the basis of technology type, the recombinant & conjugate vaccines segment was the highest shareholder in 2023.
Depending on indication, the pneumococcal disease segment held a notable share of the market in 2023.
As per end user, the pediatric segment dominated the market in 2023.
Competition Analysis
The major players in the Asia-Pacific vaccines market include Chongqing Zhifei Biological Products Co., Ltd., Bharat Biotech, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi, AstraZeneca, Pfizer, CSL, Serum Institute of India Pvt. Ltd., and Vaxine Pty Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
● Inactivated Vaccines
● Toxoid Vaccines
● Recombinant and Conjugate Vaccines
● Live Attenuated Vaccines
● Others
By Indication
● Pneumococcal Disease
● Influenza
● Human Papilloma Virus
● Meningococcal Disease
● Rotavirus
● Varicella
● Measles, Mumps, and Rubella
● Diphtheria, Pertussis, and Tetanus (DTP)
● Polio
● Hepatitis
● Other Indications
By End User
● Pediatric
● Adults
● Travelers
By Country
● Japan
● China
● India
● Australia
● South Korea
● Rest of Asia-Pacific
● Key Market Players
○ Chongqing Zhifei Biological Products Co., Ltd
○ Bharat Biotech
○ Daiichi Sankyo Company, Limited
○ Merck & Co., Inc.
○ Sanofi
○ AstraZeneca
○ Pfizer
○ CSL
○ Serum Institute of India Pvt. Ltd.
○ Vaxine Pty Ltd

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Share Analysis, By Country
4.3. Toxoid Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Share Analysis, By Country
4.4. Recombinant And Conjugate Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Share Analysis, By Country
4.5. Live Attenuated Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Share Analysis, By Country
CHAPTER 5: ASIA-PACIFIC VACCINES MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Share Analysis, By Country
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Share Analysis, By Country
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Share Analysis, By Country
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Share Analysis, By Country
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Share Analysis, By Country
5.7. Varicella
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Share Analysis, By Country
5.8. Measles, Mumps, And Rubella
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.8.2. Market Share Analysis, By Country
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.9.2. Market Share Analysis, By Country
5.10. Polio
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.10.2. Market Share Analysis, By Country
5.11. Hepatitis
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.11.2. Market Share Analysis, By Country
5.12. Other Indications
5.12.1. Key Market Trends, Growth Factors and Opportunities
5.12.2. Market Share Analysis, By Country
CHAPTER 6: ASIA-PACIFIC VACCINES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Share Analysis, By Country
6.3. Adults
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Share Analysis, By Country
6.4. Travelers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Share Analysis, By Country
CHAPTER 7: ASIA-PACIFIC VACCINES MARKET, BY COUNTRY
7.1. Market Overview
7.1.1 Market Size and Forecast, By Country
7.2. Asia-Pacific
7.2.2. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Technology Type
7.2.3. Market Size and Forecast, By Indication
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6.Japan
7.2.6.1. Market Size and Forecast, By Technology Type
7.2.6.2. Market Size and Forecast, By Indication
7.2.6.3. Market Size and Forecast, By End User
7.2.7.China
7.2.7.1. Market Size and Forecast, By Technology Type
7.2.7.2. Market Size and Forecast, By Indication
7.2.7.3. Market Size and Forecast, By End User
7.2.8.India
7.2.8.1. Market Size and Forecast, By Technology Type
7.2.8.2. Market Size and Forecast, By Indication
7.2.8.3. Market Size and Forecast, By End User
7.2.9.Australia
7.2.9.1. Market Size and Forecast, By Technology Type
7.2.9.2. Market Size and Forecast, By Indication
7.2.9.3. Market Size and Forecast, By End User
7.2.10.South Korea
7.2.10.1. Market Size and Forecast, By Technology Type
7.2.10.2. Market Size and Forecast, By Indication
7.2.10.3. Market Size and Forecast, By End User
7.2.11.Rest of Asia Pacific
7.2.11.1. Market Size and Forecast, By Technology Type
7.2.11.2. Market Size and Forecast, By Indication
7.2.11.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning,2023
CHAPTER 9: COMPANY PROFILES
9.1. Chongqing Zhifei Biological Products Co., Ltd
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Bharat Biotech
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Daiichi Sankyo Company, Limited
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Merck And Co., Inc.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Sanofi
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. AstraZeneca
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Pfizer
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. CSL
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Serum Institute Of India Pvt. Ltd.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Vaxine Pty Ltd
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. ASIA-PACIFIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 3. ASIA-PACIFIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 4. ASIA-PACIFIC VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 5. ASIA-PACIFIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 6. ASIA-PACIFIC VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 7. ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 8. ASIA-PACIFIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 9. ASIA-PACIFIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. ASIA-PACIFIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 11. ASIA-PACIFIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 12. ASIA-PACIFIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 13. ASIA-PACIFIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 14. ASIA-PACIFIC VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 15. ASIA-PACIFIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 16. ASIA-PACIFIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 17. ASIA-PACIFIC VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 18. ASIA-PACIFIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. ASIA-PACIFIC VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 20. ASIA-PACIFIC VACCINES MARKET FOR PEDIATRIC, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 21. ASIA-PACIFIC VACCINES MARKET FOR ADULTS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 22. ASIA-PACIFIC VACCINES MARKET FOR TRAVELERS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 23. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 24. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 25. ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 26. ASIA-PACIFIC VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. JAPAN VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 28. JAPAN VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 29. JAPAN VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. CHINA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 31. CHINA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 32. CHINA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. INDIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. INDIA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 35. INDIA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 37. AUSTRALIA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 38. AUSTRALIA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 39. SOUTH KOREA VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 40. SOUTH KOREA VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 41. SOUTH KOREA VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. REST OF ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 43. REST OF ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 44. REST OF ASIA-PACIFIC VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 45. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: KEY EXECUTIVES
TABLE 46. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: COMPANY SNAPSHOT
TABLE 47. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: OPERATING SEGMENTS
TABLE 48. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: PRODUCT PORTFOLIO
TABLE 49. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 50. BHARAT BIOTECH: KEY EXECUTIVES
TABLE 51. BHARAT BIOTECH: COMPANY SNAPSHOT
TABLE 52. BHARAT BIOTECH: OPERATING SEGMENTS
TABLE 53. BHARAT BIOTECH: PRODUCT PORTFOLIO
TABLE 54. BHARAT BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55. DAIICHI SANKYO COMPANY, LIMITED: KEY EXECUTIVES
TABLE 56. DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT
TABLE 57. DAIICHI SANKYO COMPANY, LIMITED: OPERATING SEGMENTS
TABLE 58. DAIICHI SANKYO COMPANY, LIMITED: PRODUCT PORTFOLIO
TABLE 59. DAIICHI SANKYO COMPANY, LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 60. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 61. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 62. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 63. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 64. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 65. SANOFI: KEY EXECUTIVES
TABLE 66. SANOFI: COMPANY SNAPSHOT
TABLE 67. SANOFI: OPERATING SEGMENTS
TABLE 68. SANOFI: PRODUCT PORTFOLIO
TABLE 69. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70. ASTRAZENECA: KEY EXECUTIVES
TABLE 71. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 72. ASTRAZENECA: OPERATING SEGMENTS
TABLE 73. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 74. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 75. PFIZER: KEY EXECUTIVES
TABLE 76. PFIZER: COMPANY SNAPSHOT
TABLE 77. PFIZER: OPERATING SEGMENTS
TABLE 78. PFIZER: PRODUCT PORTFOLIO
TABLE 79. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 80. CSL: KEY EXECUTIVES
TABLE 81. CSL: COMPANY SNAPSHOT
TABLE 82. CSL: OPERATING SEGMENTS
TABLE 83. CSL: PRODUCT PORTFOLIO
TABLE 84. CSL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 85. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
TABLE 86. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 87. SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
TABLE 88. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 89. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90. VAXINE PTY LTD: KEY EXECUTIVES
TABLE 91. VAXINE PTY LTD: COMPANY SNAPSHOT
TABLE 92. VAXINE PTY LTD: OPERATING SEGMENTS
TABLE 93. VAXINE PTY LTD: PRODUCT PORTFOLIO
TABLE 94. VAXINE PTY LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. ASIA-PACIFIC VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF ASIA-PACIFIC VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN ASIA-PACIFIC VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: ASIA-PACIFIC VACCINES MARKET
FIGURE 10. ASIA-PACIFIC VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. ASIA-PACIFIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. ASIA-PACIFIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. ASIA-PACIFIC VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. ASIA-PACIFIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. ASIA-PACIFIC VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. ASIA-PACIFIC VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 17. ASIA-PACIFIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. ASIA-PACIFIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. ASIA-PACIFIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. ASIA-PACIFIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. ASIA-PACIFIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. ASIA-PACIFIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. ASIA-PACIFIC VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. ASIA-PACIFIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. ASIA-PACIFIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. ASIA-PACIFIC VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. ASIA-PACIFIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. ASIA-PACIFIC VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 29. ASIA-PACIFIC VACCINES MARKET FOR PEDIATRIC, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 30. ASIA-PACIFIC VACCINES MARKET FOR ADULTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 31. ASIA-PACIFIC VACCINES MARKET FOR TRAVELERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 36. COMPETITIVE DASHBOARD
FIGURE 37. COMPETITIVE HEATMAP: ASIA-PACIFIC VACCINES MARKET
FIGURE 38. TOP PLAYER POSITIONING,2023
FIGURE 39. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. BHARAT BIOTECH: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. BHARAT BIOTECH: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. BHARAT BIOTECH: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. DAIICHI SANKYO COMPANY, LIMITED: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. DAIICHI SANKYO COMPANY, LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. DAIICHI SANKYO COMPANY, LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. CSL: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. CSL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. CSL: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 63. SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 64. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 65. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 66. VAXINE PTY LTD: NET SALES, 2021-2023 ($BILLION)
FIGURE 67. VAXINE PTY LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 68. VAXINE PTY LTD: REVENUE SHARE, BY REGION, 2023 (%)